Verrica Pharmaceuticals Inc (VRCA)
1.69
+0.01
(+0.60%)
USD |
NASDAQ |
Sep 27, 16:00
1.66
-0.03
(-1.78%)
After-Hours: 20:00
Verrica Pharmaceuticals Research and Development Expense (TTM): 20.10M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 20.10M |
March 31, 2024 | 22.50M |
December 31, 2023 | 20.29M |
September 30, 2023 | 18.00M |
June 30, 2023 | 14.27M |
March 31, 2023 | 12.49M |
December 31, 2022 | 12.20M |
September 30, 2022 | 12.52M |
June 30, 2022 | 13.51M |
March 31, 2022 | 13.01M |
December 31, 2021 | 15.93M |
September 30, 2021 | 14.84M |
June 30, 2021 | 16.07M |
March 31, 2021 | 16.14M |
Date | Value |
---|---|
December 31, 2020 | 15.67M |
September 30, 2020 | 17.37M |
June 30, 2020 | 15.43M |
March 31, 2020 | 15.84M |
December 31, 2019 | 15.44M |
September 30, 2019 | 16.38M |
June 30, 2019 | 16.80M |
March 31, 2019 | 16.39M |
December 31, 2018 | 12.83M |
September 30, 2018 | 9.027M |
June 30, 2018 | 6.68M |
March 31, 2018 | 4.142M |
December 31, 2017 | 3.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
12.20M
Minimum
Dec 2022
22.50M
Maximum
Mar 2024
15.90M
Average
15.76M
Median
Research and Development Expense (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 786.34M |
Zevra Therapeutics Inc | 46.33M |
scPharmaceuticals Inc | 12.16M |
TELA Bio Inc | 9.769M |
Terns Pharmaceuticals Inc | 69.23M |